Live feed09:00:00·307dPRReleasevia QuantisnowZai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational StudyByQuantisnow·Wall Street's wire, on your screen.ZLAB· Zai Lab LimitedHealth Care
